

*Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated 27 October 2016 (the “**Prospectus**”) issued by Guangdong Kanghua Healthcare Co., Ltd. (the “**Company**”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus issued by the Company for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.*

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Hong Kong Offer Shares are being offered and sold outside the United States in offshore transactions in accordance with Regulation S under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The Offer Shares have not been and will not be registered under the U.S. Securities Act and may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from or in a transaction not subject to the registration requirements of the U.S. Securities Act. There is not and it is not currently intended for there to be any public offering of securities of the Company in the United States.*

*In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may, to the extent permitted by applicable laws of Hong Kong or elsewhere, over-allocate or effect transactions with a view to stabilizing or supporting the market price of the H Shares at a level higher than that which might otherwise prevail in the open market for a limited period after Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of the applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).*

*Potential investors should be aware that stabilizing action cannot be taken to support the price of the H Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Thursday, 1 December 2016, being the 30th day after the date of closing of the application lists under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.*



**廣東康華醫療股份有限公司**  
**GUANGDONG KANGHUA HEALTHCARE CO., LTD.\***  
*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**GLOBAL OFFERING**

**Number of Offer Shares under : 84,000,000 H Shares (subject to the**  
**the Global Offering : Over-allotment Option)**  
**Number of Hong Kong Offer Shares : 8,400,000 H Shares (subject to**  
**reallocation)**  
**Number of International Offer : 75,600,000 H Shares (subject to**  
**Shares : reallocation and the Over-allotment**  
**Option)**  
**Maximum Offer Price : HK\$14.50 per Offer Share plus**  
**brokerage of 1.0%, SFC transaction**  
**levy of 0.0027% and Hong Kong**  
**Stock Exchange trading fee of**  
**0.005% (payable in full on**  
**application in Hong Kong dollars**  
**and subject to refund)**  
**Nominal Value : RMB1.00 per H Share**  
**Stock Code : 3689**

**Sole Sponsor and Sole Global Coordinator**



**Joint Bookrunners**



*\* For identification purposes only.*

Application has been made by the Company to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the H Shares, to be issued or sold pursuant to the Global Offering (including any additional H Shares which may be issued pursuant to the exercise of the Over-allotment Option).

The Global Offering comprises the Hong Kong Public Offering of initially 8,400,000 H Shares (subject to reallocation) and the International Offering of initially 75,600,000 H Shares (subject to reallocation and the Over-allotment Option) outside the United States (including to professional and institutional investors and other investors anticipated to have a sizeable demand for the International Offer Shares within Hong Kong) in offshore transactions in reliance on Regulation S under the U.S. Securities Act, representing 10% and 90% of the total number of H Shares initially being offered under the Global Offering, respectively. Please refer to the section headed “Structure of the Global Offering” in the Prospectus for more details.

Pursuant to the Over-allotment Option, the International Underwriters have the right, exercisable by the Sole Global Coordinator (on behalf of the International Underwriters) at any time from the day on which trading of the H Shares commences on the Stock Exchange until the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to an aggregate of 12,600,000 additional H Shares, representing 15% of the initial Offer Shares, at the same price per H Share under the International Offering, to cover over-allocations in the International Offering (if any).

Subject to the granting of the approval for listing of, and permission to deal in, the H Shares on the Stock Exchange and compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Stock Exchange is required to take place in CCASS on the second business day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements will be made to enable the H Shares to be admitted into CCASS.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Tuesday, 8 November 2016, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, 8 November 2016. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the websites of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company at [www.kanghuagp.com](http://www.kanghuagp.com).

The Offer Price will not be more than HK\$14.50 per Offer Share and is expected to be not less than HK\$11.60 per Offer Share. Applicants under the Hong Kong Public Offering are required to pay, on application, the maximum offer price of HK\$14.50 per Offer Share together with brokerage of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$14.50 per Offer Share.

**Applications for Hong Kong Offer Shares will only be considered on the basis of the terms and conditions of the Prospectus, the Application Forms and the designated website [www.eipo.com.hk](http://www.eipo.com.hk) for the White Form eIPO.**

Applicants who would like to be allotted Hong Kong Offer Shares registered in their own names should (i) complete and sign the **WHITE** Application Forms; or (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at [www.eipo.com.hk](http://www.eipo.com.hk) under the **White Form eIPO** service. Applicants who would like to have the allotted Hong Kong Offer Shares registered in the name of HKSCC Nominees and deposited directly into CCASS for credit to their designated CCASS Participant's stock accounts or their CCASS Investor Participant stock accounts should (i) complete and sign the **YELLOW** Application Forms; or (ii) give electronic application instructions to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Thursday, 27 October 2016 until 12:00 noon on Tuesday, 1 November 2016 from:

1. the following offices of the Hong Kong Underwriters:

**China International Capital Corporation Hong Kong Securities Limited**  
29/F, One International Finance Centre  
1 Harbour View Street  
Central  
Hong Kong

**CMB International Capital Limited**  
Units 1803-4, 18/F, Bank of America Tower  
12 Harcourt Road  
Central  
Hong Kong

**ABCI Securities Company Limited**  
10/F, Agricultural Bank of China Tower  
50 Connaught Road  
Central  
Hong Kong

**BOCOM International Securities Limited**  
9/F, Man Yee Building  
68 Des Voeux Road Central  
Central  
Hong Kong

**Zhaobangji International Capital Limited**  
Units 1&17, 19/F, China Merchants Tower  
Shun Tak Centre  
168-200 Connaught Road Central  
Hong Kong

or

2. any of the following branches of the receiving bank:

**Bank of China (Hong Kong) Limited**

<b>District</b>	<b>Branch Name</b>	<b>Address</b>
<b>Hong Kong Island</b>	Bank of China Tower Branch	3/F, 1 Garden Road
<b>Kowloon</b>	Shanghai Street (Mong Kok) Branch	611-617 Shanghai Street, Mong Kok
	194 Cheung Sha Wan Road Branch	194-196 Cheung Sha Wan Road, Sham Shui Po, Kowloon
	Hoi Yuen Road Branch	55 Hoi Yuen Road, Kwun Tong
	Tseung Kwan O Plaza Branch	Shop 112-125, Level 1, Tseung Kwan O Plaza, Tseung Kwan O

**New Territories**      City One Sha Tin Branch      Shop Nos. 24-25, G/F,  
Fortune City One Plus,  
No. 2 Ngan Shing Street,  
Sha Tin

Copies of the Prospectus, together with the **YELLOW** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Thursday, 27 October 2016 until 12:00 noon on Tuesday, 1 November 2016 from the Depository Counter of HKSCC at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker, who may have the **YELLOW** Application Forms and copies of the Prospectus available.

Both the **WHITE** and **YELLOW** Application Forms completed in all respects in accordance with the instructions printed thereon, to which cheques or banker's cashier orders payable to "BANK OF CHINA (HONG KONG) NOMINEES LIMITED — GUANGDONG KANGHUA HEALTHCARE PUBLIC OFFER" should be securely stapled and deposited in the special collection boxes provided at any of the branches referred to above on the following dates during the following times:

Thursday, 27 October 2016 — 9:00 a.m. to 5:00 p.m.  
Friday, 28 October 2016 — 9:00 a.m. to 5:00 p.m.  
Saturday, 29 October 2016 — 9:00 a.m. to 1:00 p.m.  
Monday, 31 October 2016 — 9:00 a.m. to 5:00 p.m.  
Tuesday, 1 November 2016 — 9:00 a.m. to 12:00 noon

Applicants applying by the **White Form eIPO** may submit application through the designated website at [www.eipo.com.hk](http://www.eipo.com.hk) from 9:00 a.m. on Thursday, 27 October 2016 until 11:30 a.m. on Tuesday, 1 November 2016 or such later time as described in the section headed "How to Apply for the Hong Kong Offer Shares — 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus (24 hours daily, except on the last application day).

CCASS Participants can input electronic application instructions from 9:00 a.m. on Thursday, 27 October 2016 until 12:00 noon on Tuesday, 1 November 2016 (except on Saturday, 29 October 2016 and Sunday, 30 October 2016), or such later date as may apply in case of certain bad weather conditions as described in "How to Apply for the Hong Kong Offer Shares — 10. Effect of Bad Weather on the Opening of the Application Lists" in the Prospectus.

Please refer to the "Structure of the Global Offering" and "How to Apply for Hong Kong Offer Shares" sections in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to announce the final Offer Price, the level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares (i) in South China Morning Post (in English); (ii) Hong Kong Economic Times (in Chinese); (iii) on the Company's website at [www.kanghuagp.com](http://www.kanghuagp.com); and (iv) the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) on or before Monday, 7 November 2016.

Results of allocations of the Hong Kong Public Offering and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be made available in a manner described in the section headed "How to Apply for the Hong Kong Offer Shares — 11. Publication of Results" in the Prospectus on Monday, 7 November 2016.

The Company will not issue temporary documents of title or receipt for application fees received. Share certificates will only become valid certificates of title provided that the Hong Kong Public Offering has become unconditional in all respects and the right of termination described in the section headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination" in the Prospectus has lapsed, which is expected to be at 8:00 a.m. on Tuesday, 8 November 2016.

Dealings in the H Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Tuesday, 8 November 2016. The H Shares will be traded in board lots of 200 H Shares each under the Company's stock code 3689.

By order of the Board of Directors  
**Guangdong Kanghua Healthcare Co., Ltd.**  
**WANG Junyang**  
*Chairman and Executive Director*

Hong Kong, 27 October 2016

*As at the date of this announcement, the executive Directors are Mr. WANG Junyang, Mr. CHEN Wangzhi, Mr. WONG Wai Hung Simon and Ms. WANG Aiqin; the non-executive Director is Mr. LV Yubo and the independent non-executive Directors are Mr. YEUNG Ming Lai, Dr. CHEN Keji and Mr. CHAN Sing Nun.*

*Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong Kong Economic Times (in Chinese).*